pCPAO

pan-Canadian Pharmaceutical Alliance (pCPA): October 2018 Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of October 31, 2018. The key highlights since the September update are: 6 new drug products have initiated pCPA negotiations, for a total of 57 active negotiations; 2 negotiations were completed for a total of 216 completed negotiations; and 1 negotiation was closed since the last…

Panel 4: Pan-Canadian Pharmaceutical Alliance   Panel Description: This panel will focus on recent events surrounding the pCPA and how public payers believe that PMPRB reform may impact upcoming pCPA negotiations. Moderator: Sherry O’Quinn Panelists: Imran Ali, Jessica Arias and Heather McDonald Sherry O’Quinn: Our focus is on recent events around the pCPA and the pharmaceutical landscape. A lot of this discussion is framed around healthcare sustainability. Here to take…

pan-Canadian Pharmaceutical Alliance (pCPA): September 2018 Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of September 30, 2018. This month, MORSE Consulting Inc. provides our standard update along with two charts demonstrating the trends for the average time under consideration and average duration of negotiation for completed and closed files from August 2017 to September 2018. Of note: Average Time…

pCPA Biosimilars/Biologics Policy Directions Webinar   On Tuesday September 25, 2018 the pan-Canadian Pharmaceutical Alliance Office (pCPAO) hosted a one-hour webinar for industry to introduce the Biologics Policy Directions and pCPA Negotiations document. The objectives of the webinar were to: Present the pCPA Biologics Policy Directions & pCPA Negotiations document; and Invite and address industry feedback. This edition of MORSE Signals provides an overview of the webinar and provides key…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The August 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: 7 negotiations were completed, while none were closed for a total of 235 completed/closed negotiations; 9 new drug products have initiated pCPA negotiations, for a total of 48 active negotiations; No new drug products were added to the “No pCPA Negotiations”…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The July 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: 9 negotiations were completed, while none were closed for a total of 228 completed/closed negotiations; 8 new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; No new drug products were added to the “No pCPA Negotiations”…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The June 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while one negotiation was closed for a total of 193 completed negotiations and 26 closed negotiations; Eight new drug products have initiated pCPA negotiations, for a total of 47 active negotiations; No new drug products were added…

pCPA Brand Process Guidelines Webinar   On Friday, June 22nd, 2018 the pan-Canadian Pharmaceutical Alliance Office (pCPAO) hosted an industry consultation session via webinar, on the newly completed pCPA Brand Process Guidelines (“the Guidelines”). The objective of this webinar was to: introduce the Guidelines and supportive documents developed by the pCPA; and invite industry’s initial feedback. This edition of MORSE Signals provides an overview of the webinar and outlines key…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The May 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while three more were closed for a total of 215 completed/closed negotiations; Three new drug products have initiated pCPA negotiations, for a total of 42 active negotiations; One new drug product was added to the “No pCPA…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The April 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; One negotiation was completed (none closed), for a total of 208 joint completed/closed negotiations; and No new drug products were added to the “No pCPA Negotiations”…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The March 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 40 active negotiations; Two negotiations have been completed (none closed), for a total of 207 joint completed/closed negotiations; and One new drug product was added to the…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The February 28, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Five negotiations have been completed/closed, for a total of 205 joint completed/closed negotiations; and No new drug products were added to the “No pCPA…

pCPA Monthly Trends & Insights – January 2018   The January 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Four negotiations have been completed/closed, for a total of 200 joint completed/closed negotiations; and No new drug products were added to the “No…

MORSE Consulting has prepared a Year in Review infographic to highlight some key metrics surrounding the pCPA’s activities in 2017. This analysis highlights completed negotiations broken down in a number of different ways as well as several initiation and negotiation timing measures. MORSE concludes the analysis with our overall perspective on pCPA’s activities over the past year.   Click here to view full-size infographic   Click here to view full-size…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The December 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Five new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Eight negotiations have been completed/closed, for a total of 196 joint completed/closed negotiations; and One new drug product was added to…